Controversies in Mitral Surgery

Unless otherwise noted, speakers have nothing to disclose.

Moderators

Michael Halkos, MD
Disclosure: Medtronic: Advisory Board (Ongoing)

Marc Gillinov, MD

Presentations

  1. Surgical and Transcatheter Mitral Valve Therapy: Medicare Utilization and Reimbursement
    Aakash M. Shah, MD
     
  2. Is It TAVR All Over Again? Transcatheter Treatment of Degenerative MR
    Vinod Thourani, MD
    Disclosure: abbott vascular: Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker (Ongoing); Artivion: Consultant (Ongoing); AtriCure: Consultant (Ongoing); Boston Scientific: Consultant (Ongoing); dasi simultions: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Edwards Life Science: Advisory Board (Ongoing), Speaker (Ongoing); Jenavalve: Consultant (Ongoing); shockwave: Consultant (Ongoing)
     
  3. PRIMARY Trial: Why Are We Doing This and What Does This Mean for Surgical Management of Degenerative Mitral Disease?
    Joanna Chikwe, MD
     
  4. Panel Discussion
     
  5. The Role of Surgery in Atrial Functional MR
    Tsuyoshi Kaneko, MD
    Disclosure: Medtronic: Consultant (Ongoing), Speaker (Ongoing); Abbott: Consultant (Ongoing); Edwards Life Science: Advisory Board (Ongoing), Consultant (Ongoing), Speaker (Ongoing)
     
  6. Panel Discussion
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Activity opens: 
02/01/2023
Activity expires: 
02/01/2026
Cost:
$0.00
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Unless otherwise noted, speakers have nothing to disclose.

Moderators

Michael Halkos, MD
Disclosure: Medtronic: Advisory Board (Ongoing)

Marc Gillinov, MD

Presentations

  1. Surgical and Transcatheter Mitral Valve Therapy: Medicare Utilization and Reimbursement
    Aakash M. Shah, MD
     
  2. Is It TAVR All Over Again? Transcatheter Treatment of Degenerative MR
    Vinod Thourani, MD
    Disclosure: abbott vascular: Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker (Ongoing); Artivion: Consultant (Ongoing); AtriCure: Consultant (Ongoing); Boston Scientific: Consultant (Ongoing); dasi simultions: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Edwards Life Science: Advisory Board (Ongoing), Speaker (Ongoing); Jenavalve: Consultant (Ongoing); shockwave: Consultant (Ongoing)
     
  3. PRIMARY Trial: Why Are We Doing This and What Does This Mean for Surgical Management of Degenerative Mitral Disease?
    Joanna Chikwe, MD
     
  4. Panel Discussion
     
  5. The Role of Surgery in Atrial Functional MR
    Tsuyoshi Kaneko, MD
    Disclosure: Medtronic: Consultant (Ongoing), Speaker (Ongoing); Abbott: Consultant (Ongoing); Edwards Life Science: Advisory Board (Ongoing), Consultant (Ongoing), Speaker (Ongoing)
     
  6. Panel Discussion